Clinical trials in recurrent ovarian cancer - PubMed (original) (raw)
Review
doi: 10.1097/IGC.0b013e31821bb8aa.
Edward Trimble, Anna Tinker, David Alberts, Elisabeth Avall-Lundqvist, Mark Brady, Philipp Harter, Sandro Pignata, Eric Pujade-Lauraine, Jalid Sehouli, Ignace Vergote, Philip Beale, Rudd Bekkers, Paula Calvert, Lawrence Copeland, Ros Glasspool, Antonio Gonzalez-Martin, Dionysis Katsaros, Jae Won Kim, Brigitte Miller, Diane Provencher, Lawrence Rubinstein, Mostafa Atri, Alain Zeimet, Monica Bacon, Henry Kitchener, Gavin C E Stuart; Gynecologic Cancer InterGroup
Affiliations
- PMID: 21543939
- DOI: 10.1097/IGC.0b013e31821bb8aa
Review
Clinical trials in recurrent ovarian cancer
Michael Friedlander et al. Int J Gynecol Cancer. 2011 May.
Abstract
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?
Similar articles
- First-line therapy in ovarian cancer trials.
Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Thigpen T, et al. Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d. Int J Gynecol Cancer. 2011. PMID: 21543937 Review. - The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.
Bacon M, Kitchener H, Stuart GC, Vermorken JB; Gynecologic Cancer InterGroup and participants of 4th Ovarian Cancer Consensus Conference. Bacon M, et al. Int J Gynecol Cancer. 2011 May;21(4):746-9. doi: 10.1097/IGC.0b013e31821bb446. Int J Gynecol Cancer. 2011. PMID: 21543935 - 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E; participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gynecologic Cancer Intergroup. Stuart GC, et al. Int J Gynecol Cancer. 2011 May;21(4):750-5. doi: 10.1097/IGC.0b013e31821b2568. Int J Gynecol Cancer. 2011. PMID: 21543936 Review. - Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
Joly F, Hilpert F, Okamoto A, Stuart G, Ochiai K, Friedlander M; of the participants of the 5th Ovarian Cancer Consensus Conference. Joly F, et al. Eur J Cancer. 2017 Jun;78:133-138. doi: 10.1016/j.ejca.2017.03.019. Epub 2017 Apr 25. Eur J Cancer. 2017. PMID: 28448857 - FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL. Herzog TJ, et al. Gynecol Oncol. 2017 Oct;147(1):3-10. doi: 10.1016/j.ygyno.2017.08.012. Epub 2017 Aug 24. Gynecol Oncol. 2017. PMID: 28844539 Review. No abstract available.
Cited by
- Introduction to managing patients with recurrent ovarian cancer.
Gabra H. Gabra H. EJC Suppl. 2014 Dec;12(2):2-6. doi: 10.1016/S1359-6349(15)70003-0. Epub 2015 Jan 13. EJC Suppl. 2014. PMID: 26759525 Free PMC article. - Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA, Burger IA, Goldman DA, Miccò M, Sosa RE, Weber W, Chi DS, Hricak H, Sala E. Vargas HA, et al. Eur Radiol. 2015 Nov;25(11):3348-53. doi: 10.1007/s00330-015-3729-9. Epub 2015 Apr 28. Eur Radiol. 2015. PMID: 25916387 Free PMC article. - Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma.
Tomasova K, Seborova K, Kroupa M, Horak J, Kavec M, Vodickova L, Rob L, Hruda M, Mrhalova M, Bartakova A, Bouda J, Fleischer T, Kristensen VN, Vodicka P, Vaclavikova R. Tomasova K, et al. Heliyon. 2024 Jun 29;10(13):e33525. doi: 10.1016/j.heliyon.2024.e33525. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39050459 Free PMC article. - DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N, Mimoto R, Yanaihara N, Imawari Y, Hirooka S, Okamoto A, Yoshida K. Yamaguchi N, et al. Tumour Biol. 2015 Aug;36(8):5913-23. doi: 10.1007/s13277-015-3264-y. Epub 2015 Feb 25. Tumour Biol. 2015. PMID: 25712377 - Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.
Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U. Gurioli G, et al. Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789. Int J Mol Sci. 2022. PMID: 36555431 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous